Skip to main content
. 2020 May 5;9(4):382–396. doi: 10.1159/000507022

Fig. 2.

Fig. 2

PFS and OS in patients with advanced HCC who received lenvatinib. a Comparing PFS in first- and second- or later-line Child-Pugh class A patients (blue line: first line, red line: second or later-line). b Comparing OS in first- and second- or later-line Child-Pugh class A patients (blue line: first line, red line: second or later line). c Comparing PFS in a high burden of intrahepatic lesions and other Child-Pugh class A patients (blue line: high burden of intrahepatic lesions, red line: others). d Comparing OS in a high burden of intrahepatic lesions and other Child-Pugh class A patients (blue line: high burden of intrahepatic lesions, red line: others). e Comparing PFS in Child-Pugh classes A and B patients (blue line: Child-Pugh class A, red line: Child-Pugh class B). f Comparing OS in Child-Pugh classes A and B patients (blue line: Child-Pugh class A, red line: Child-Pugh class B). PFS, progression-free survival.